Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Hepatitis B Immunoglobulin (HBIG) is a form of passive immunization when given shortly before or soon after exposure to hepatitis B virus. It is also administered in combination with HBV vaccines to the newborns of HBsAg positive mothers.[1][2]
Secondary Prevention
Secondary Prevention
Hepatitis B Immunoglobulin
HBIG provides passively acquired anti-HBs and temporary protection (3-6 months) when administered in standard doses. HBIG is typically used as an adjunct to hepatitis B vaccine for postexposure immunoprophylaxis to prevent HBV infection. HBIG administered alone is the primary means of protection after an HBV exposure for nonresponders to hepatitis B vaccination.[1][2]
HBIG is similar to conventional IG preparations except that it is prepared from plasma preselected for a high titre of anti-HBs (>100 000 IU/ml of anti-HBs). The plasma is screened to eliminate donors who are positive for HBsAg, antibodies to HIV and hepatitis C virus (HCV), and HCV RNA:[1]
HBIG protects by passive immunization if given shortly before or soon after exposure to HBV.
The protection is immediate, but it lasts only 3 to 6 months.
HBIG is not recommended as pre-exposure prophylaxis because of high cost, limited availability, and short-term effectiveness. HBIG is generally not affordable in developing countries.
HBIG should be given to adults within 48 hours of HBV exposure.
Maternal-neonatal transmission of HBV and the subsequent development of chronic hepatitis B in infected children is reduced drastically when HBIG is given to the newborn babies of HBV carrier mothers in conjunction with the first dose of the HB vaccine.
Postexposure prophylaxis algorythm Adapted from World Health Organization[3]Summary of Recommendations for Counseling and Prevention of Transmission of Hepatitis B from Individuals with Chronic HBV Infection: AASLD Practice Guidelines [4]
Summary of Recommendations for Counseling and Prevention of Transmission of Hepatitis B from Individuals with Chronic HBV Infection: AASLD Practice Guidelines [4]
“2. Persons who are positive only for anti-HBc and who are from a low endemic area with no risk factors for HBV should be given the full series of hepatitis B vaccine.”
“5. Persons who remain at risk for HBV infection such as infants of HBsAg-positive mothers, health care workers, dialysis patients, and sexual partners of carriers should be tested for response to vaccination.
Postvaccination testing should be performed at 9 to 15 months of age in infants of carrier mothers and 1-2 months after the last dose in other persons.
Follow-up testing of vaccine responders is recommended annually for chronic hemodialysis patients.”
